Breaking News, Collaborations & Alliances

AstraZeneca, VaxEquity Enter RNA Therapeutics Alliance

Aims to optimize and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programs in AstraZeneca's pipeline.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca entered an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.   The strategic, long-term research collaboration aims to optimize and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programs. AstraZeneca will provide VaxEquity with R&D funding and development, approval and sales based milestones totaling up to $195...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters